Antroquinonol for NSCLC Lung Cancer

Model: Antroquinonol for NSCLC Lung Cancer

Booth No: L318

Characteristic

Golden Biotechnology Corp, an advanced biopharma dedicated to innovative new drugs. The new drug, Antroquinonol (HOCENA), a NCE with multi-functions, it can inhibit Ras targeting pathway and PI3K/Akt/mTOR pathway. Antroquinonol has completed Phase 2 trials in NSCLC, AML, pancreatic cancer and COVID-19. Report of Phase 2 trial for first-line treatment of meta. pancreatic cancer showed much longer OS than standard therapy. It has received orphan drug designation (ODD) from the FDA for AML, pancreatic cancer, and HCC and for pancreatic cancer in EU. GoldenBiotech welcomes inquiries and discussions from potential partners.

Menu

Antroquinonol for NSCLC Lung Cancer

Characteristic

Other Products

Products you may be interested in

Highest Rated Products